The efficacy and safety of Jiedu Tongluo granules for treating post-stroke depression with qi deficiency and blood stasis syndrome: Study protocol for a randomized controlled trial

Trials

Volumn 19, Issue 1, 2018, Pages

  Zhao, Ai mei ^a,b   Qiu, Wen ran ^a,b   Mao, Li jun ^b   Ren, Jun guo ^b   Xu, Li ^b   Yao, Ming jiang ^b   Bilinksi, Kellie ^c   Chang, Dennis ^c   Liu, Jian xun ^b,c  

^a BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

^b INSTITUTE OF CHINESE MATERIA MEDICA   (China)

^c UNIVERSITY OF WESTERN SYDNEY   (Australia)

Author keywords

Chinese herbal medicine; Jiedu Tongluo granules; Post stroke depression; Qi deficiency and blood stasis syndrome; Randomized controlled trial

Indexed keywords

HERBACEOUS AGENT; INTERLEUKIN 6; INTERLEUKIN 8; JIEDU TONGLUO; PLACEBO; UNCLASSIFIED DRUG; TONGLUO;

ADULT; AGED; ARTICLE; BARTHEL INDEX; BLOOD CELL COUNT; BLOOD STASIS SYNDROME; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ELECTROCARDIOGRAPHY; HAMILTON DEPRESSION RATING SCALE; HEMATOLOGIC DISEASE; HUMAN; INDEPENDENCE; KIDNEY FUNCTION TEST; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PILOT STUDY; POST-STROKE DEPRESSION; QI DEFICIENCY; RANDOMIZED CONTROLLED TRIAL; RANKIN SCALE; SIDE EFFECT; VITAL SIGN; CEREBROVASCULAR ACCIDENT; CHINESE MEDICINE; DEPRESSION; MEDICATION COMPLIANCE; MIDDLE AGED; PSYCHOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); VERY ELDERLY;

ACTIVITIES OF DAILY LIVING; AGED; AGED, 80 AND OVER; DEPRESSION; DOUBLE-BLIND METHOD; DRUGS, CHINESE HERBAL; HUMANS; MEDICATION ADHERENCE; MEDICINE, CHINESE TRADITIONAL; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PILOT PROJECTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE;

EID: 85046675158     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/s13063-018-2633-4     Document Type: Article

References (34)

1. Robinson RG, Jorge RE. Post-stroke depression: a review. Am J Psychiatr. 2015;173(3):221-31.
2. Lenzi GL, Altieri M, Maestrini I. Post-stroke depression. Rev Neurol. 2008;164(10):837-40.
3. Hackett ML, Köhler S, O'Brien JT, et al. Neuropsychiatric outcomes of stroke. Lancet Neurol. 2014;13(5):525-34.
4. Hackett ML, Pickles K. Part I: frequency of depression after stroke: an updated systematic review and meta-analysis of observational studies. Int J Stroke. 2014;9(8):1017-25.
5. Ayerbe L, Ayis S, Wolfe CDA, et al. Natural history, predictors and outcomes of depression after stroke: systematic review and meta-analysis. Br J Psychiatry. 2013;202(1):14-21.
6. Kutlubaev MA, Hackett ML. Part II: predictors of depression after stroke and impact of depression on stroke outcome: an updated systematic review of observational studies. Int J Stroke. 2014;9(8):1026-36.
7. Bartoli F, Lillia N, Lax A, et al. Depression after stroke and risk of mortality: a systematic review and meta-analysis. Stroke Res Treat. 2013;2013:862978.
8. Deng L, Sun X, Qiu S, et al. Interventions for management of post-stroke depression: A Bayesian network meta-analysis of 23 randomized controlled trials. Sci Rep. 2017;7(1). https://doi.org/10.1038/s41598-017-16663-0.
9. Hackett ML, Anderson CS, House A, et al. Interventions for treating depression after stroke. Cochrane Libr. 2008; https://doi.org/10.1002/14651858.CD003437.pub3.
10. Coupland C, Dhiman P, Morriss R, et al. Antidepressant use and risk of adverse outcomes in older people: population based cohort study. BMJ. 2011;343:d4551.
11. Zeng LF, Cao Y, Wang L, et al. Role of medicinal plants for Liver-Qi regulation adjuvant therapy in post-stroke depression: a systematic review of literature. Phytother Res. 2016; https://doi.org/10.1002/ptr.5740.
12. Meng F, Hou S, Yuan D, et al. Modern literature review of syndrome differentiation of ischemic stroke. Liaoning J Trad Chin Med. 2014;(2):207-10. [Article in Chinese]. https://doi.org/10.13192/j.issn.1000-1719.2014.02.005.
13. Duan H-L. Data mining and analysis of Professor Yujie Liu's experience in treating post-stroke depression-based on TCM Inheritance Assisted System. Method Mod Distance Educ Tradit Chin Med. 2016;14(3):52-8. [Article in Chinese].
14. Cao SJ, Hu G-J. Observation on curative effect of Yiqi Huoxue Jieyu Decoction on post-stroke depression. J Anhui Univ Chin Med. 2017;36(3):12-5. [Article in Chinese].
15. Song WT, Xu L, Ren JX, et al. Effect of Jiedu Tongluo Capsule on Qi-relieving depression in rats with depression after stroke. World Sci Technol. 2015;(7):1380-5. [Article in Chinese]. http://kns.cnki.net/KCMS/detail/detail.aspx?dbcode=CJFQ&dbname=CJFDLAST2015&filename=SJKX201507012&v=MTI0NzdyL0xOaWZBZHJHNEg5VE1xSTlFWm9SOGVYMUx1eFlTN0RoMVQzcVRyV00xRnJDVVJMS2ZZK1JwRmlEaFc=.
16. Wei-Yi O, Tahira F, Hwee-Ling K, et al. Protective effects of ginseng on neurological disorders. Frontiers in Aging Neuroscience, 2015;7:129. https://doi.org/10.3389/fnagi.2015.00129.
17. Xiang H, Liu Y, Zhang B, et al. The antidepressant effects and mechanism of action of total saponins from the caudexes and leaves of Panax notoginseng in animal models of depression. Phytomedicine. 2011;18(8):731-8.
18. Ye R, Kong X, Yang Q, et al. Ginsenoside rd in experimental stroke: superior neuroprotective efficacy with a wide therapeutic window. Neurotherapeutics. 2011;8(3):515-25.
19. Kumar Singh S, Barreto GE, Aliev G, et al. Ginkgo biloba as an alternative medicine in the treatment of anxiety in dementia and other psychiatric disorders. Curr Drug Metab. 2017;18(2):112-9.
20. Tulsulkar J, Shah ZA. Ginkgo biloba prevents transient global ischemia-induced delayed hippocampal neuronal death through antioxidant and anti-inflammatory mechanism. Neurochem Int. 2013;62(2):189-97.
21. Jiang B, Xiong Z, Yang J, et al. Antidepressant-like effects of ginsenoside Rg1 are due to activation of the BDNF signalling pathway and neurogenesis in the hippocampus. Br J Pharmacol. 2012;166(6):1872.
22. Hou Y, Aboukhatwa MA, Lei DL, et al. Anti-depressant natural flavonols modulate BDNF and beta amyloid in neurons and hippocampus of double TgAD mice. Neuropharmacology. 2010;58(6):911-20.
23. Wang Xin-de. All kinds of cerebrovascular disease diagnosis points. Chin J Neurol, 1996;379-380. [Article in Chinese].
24. Chinese Medical Association psychiatric branch, editor. Classification and Diagnostic Criteria for Mental Disorders in China. 3rd ed. Jinan: Shandong Science and Technology Press; 2001. p. 87-8. [Article in Chinese].
25. Zhen XY. Guidelines for clinical research of new Chinese medicine. Beijing: China Medical Science Press; 2002. [Book in Chinese].
26. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(1):56.
27. Brott T, Adams HP, Olinger CP, et al. Measurements of acute cerebral infarction: a clinical examination scale. Stroke. 1989;20(7):864.
28. Bloch RF. Interobserver agreement for the assessment of handicap in stroke patients. Stroke. 1988;19(5):604-7.
29. Mahoney FJ, Barthel DW. Functional evaluation: the Barhel Index[J]. Md Med J. 1965;14(14):61.
30. State Administration of Traditional Chinese Medicine. Criatia of diagnosis and therapeutic effect of disease and syndromes in traditional Chinese medicine [M]: Nanjing University Press; 1994. [Book in Chinese].
31. Kang HJ, Bae KY, Kim SW, et al. Effects of interleukin-6, interleukin-18, and statin use, evaluated at acute stroke, on post-stroke depression during 1-year follow-up. Psychoneuroendocrinology. 2016;72:156-60.
32. Bahramabadi R, Fathollahi MS, Hashemi SM, et al. Serum levels of IL-6, IL-8, TNF-α, and TGF-β in chronic HBV-infected patients: effect of depression and anxiety. Lab Med. 2017;7(1):3757.
33. Towfighi A, Ovbiagele B, El Husseini N, et al. Post stroke depression: a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2017;48(2):e30-43.
34. Villa RF, Ferrari F, Moretti A. Post-stroke depression: mechanisms and pharmacological treatment. Pharmacol Ther. 2017. https://doi.org/10.1016/j.pharmthera.2017.11.005.